Breaking News Instant updates and real-time market news.

MMP

Magellan Midstream

$64.28 /

-0.72 (-1.11%)

09:02
01/21/20
01/21
09:02
01/21/20
09:02

Magellan Midstream raises dividend 1% to $1.0275

The board of directors of Magellan Midstream Partners has increased the partnership's quarterly cash distribution to $1.0275 per unit for the period Oct. 1 through Dec. 31, 2019, representing the 71st distribution increase since its initial public offering in 2001. The Q4 distribution is 3% higher than the Q4 of FY18 distribution of 99.75c per unit and represents an approximate 1% increase over the Q3 distribution of $1.02. For the year, Magellan declared distributions of $4.065 per unit for 2019, or 5% higher than distributions of $3.87 per unit for 2018.

  • 30

    Jan

MMP Magellan Midstream
$64.28 /

-0.72 (-1.11%)

01/14/20 Barclays
Barclays changes ratings in MLPs, Diversified Natural Gas space
01/14/20 Barclays
Magellan Midstream upgraded to Overweight from Equal Weight at Barclays
01/08/20 Wolfe Research
Magellan Midstream upgraded to Peer Perform from Underperform at Wolfe Research
01/07/20 Wells Fargo
Magellan Midstream upgraded to Overweight at Wells Fargo

TODAY'S FREE FLY STORIES

General news
FX Update: Risk-off positioning underpinned the yen » 02:55
02/28/20
02/28
02:55
02/28/20
02:55

FX Update: Risk-off…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return tomorrow

Get Free Trial

Recommendations
Glaukos price target lowered to $62 from $80 at Piper Sandler » 23:11
02/27/20
02/27
23:11
02/27/20
23:11
GKOS

Glaukos

$61.32 /

-0.03 (-0.05%)

Piper Sandler analyst…

Piper Sandler analyst Matt O'Brien lowered the firm's price target on Glaukos to $62 from $80 after its Q4 results and below-consensus guidance for FY20, with the management anticipating domestic glaucoma business to be soft due to competitive pressure. The analyst still keeps his Overweight rating on the shares however, stating that he still believes that the franchise can be stabilized and grow in the future. O'Brien adds that he remains positive on the company's robust pipeline and further notes that the integration of Avedro is proceeding "fine".

ShowHide Related Items >><<
03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Earnings
B2Gold reports Q4 EPS 17c , consensus 2c » 23:03
02/27/20
02/27
23:03
02/27/20
23:03
BTG

B2Gold

$4.27 /

-0.36 (-7.78%)

Reports Q4 revenue…

Reports Q4 revenue $313.7M, consensus $204.25M. Reports Q4 gold production 245.1K oz.

ShowHide Related Items >><<
03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Recommendations
CytomX Therapeutics heading for platform validation, says Piper Sandler » 20:28
02/27/20
02/27
20:28
02/27/20
20:28
CTMX

CytomX Therapeutics

$7.12 /

-0.135 (-1.86%)

Piper Sandler analyst…

Piper Sandler analyst Joseph Catanzaro keeps his Overweight rating and $18 price target on CytomX Therapeutics after its Q4 results and guidance for data readouts in 2020 and into 2021. The analyst notes that with the initial/additional data expected for the company in 2020 for four Probody programs, the stock valuation is given the company's prospects little credit.

ShowHide Related Items >><<
03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Earnings
Notable companies reporting before tomorrow's open » 20:25
02/27/20
02/27
20:25
02/27/20
20:25
W

Wayfair

$70.05 /

-1.29 (-1.81%)

, SPR

Spirit AeroSystems

$56.49 /

-2.64 (-4.46%)

, FL

Foot Locker

$33.63 /

-0.675 (-1.97%)

Notable companies…

Notable companies reporting before tomorrow's open, with earnings consensus, include Wayfair (W), consensus ($2.65)... Spirit AeroSystems (SPR), consensus $1.65... Foot Locker (FL), consensus $1.58.

ShowHide Related Items >><<
03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Recommendations
Piper Sandler continues to like Rigel Pharmaceuticals setup » 20:18
02/27/20
02/27
20:18
02/27/20
20:18
RIGL

Rigel Pharmaceuticals

$2.05 /

-0.13 (-5.96%)

Piper Sandler analyst…

Piper Sandler analyst Christopher Raymond keeps his Overweight rating and $8 price target on Rigel Pharmaceuticals after its Q4 results, saying that with the management pre-announcing the Tavalisse revenue and "encouraging metrics" last month, there was little surprise in the release. The analyst notes that he remains positive heading into 2020, with an earlier-line ITP patient Tavalisse uptake serving as a tailwind for the shares.

ShowHide Related Items >><<
03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Downgrade
Teladoc downgraded to Sector Weight from Overweight at KeyBanc » 20:00
02/27/20
02/27
20:00
02/27/20
20:00
TDOC

Teladoc

$135.17 /

+18.285 (+15.64%)

KeyBanc analyst Donald…

KeyBanc analyst Donald Hooker downgraded Teladoc to Sector Weight from Overweight.

ShowHide Related Items >><<
03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Syndicate
Passage Bio 12M share IPO priced at $18.00 » 19:37
02/27/20
02/27
19:37
02/27/20
19:37
PASG

Passage Bio

$0.00 /

+ (+0.00%)

The deal size was…

The deal size was increased from 7.4M to 12M shares and price at the top of $16.00-$18.00 range. JPMorgan, Goldman Sachs and Cowen are acting as joint book running managers for the offering.

ShowHide Related Items >><<
  • 28
    Feb
Hot Stocks
ESA says 'moving full speed ahead' with E3 despite coronavirus concerns » 19:26
02/27/20
02/27
19:26
02/27/20
19:26
NTDOY

Nintendo

$0.00 /

+ (+0.00%)

, SNE

Sony

$60.90 /

-3.05 (-4.77%)

, MSFT

Microsoft

$158.00 /

-12.2 (-7.17%)

, TCEHY

Tencent

$0.00 /

+ (+0.00%)

, ATVI

Activision Blizzard

$58.32 /

-1.02 (-1.72%)

, EA

Electronic Arts

$102.88 /

-3.62 (-3.40%)

, TTWO

Take-Two

$108.04 /

-1.63 (-1.49%)

, UBSFY

Ubisoft

$0.00 /

+ (+0.00%)

, CCOEY

Capcom

$0.00 /

+ (+0.00%)

Commenting on how the…

Commenting on how the recent outbreak of coronavirus may affect this summer's Electronic Entertainment Expo, or E3, an Entertainment Software Association spokesperson provided the following statement to The Fly: "Everyone is watching the situation very closely. We will continue to be vigilant, as our first priority is the health, wellness and safety of all of our exhibitors and attendees. Given what we know at this time, we are moving ahead full speed with E3 2020 planning. Exhibit and registration sales are on track for an exciting show in June." Companies in the video game space include Nintendo (NTDOY), Sony (SNE), Microsoft (MSFT), Tencent (TCEHY), Activision Blizzard (ATVI), Electronic Arts (EA), Take-Two (TTWO), Ubisoft (UBSFY), and Capcom (CCOEY).

ShowHide Related Items >><<
03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Recommendations
Oyster Point Pharma price target raised to $60 from $35 at Piper Sandler » 19:21
02/27/20
02/27
19:21
02/27/20
19:21
OYST

Oyster Point Pharma

$34.15 /

-6.37 (-15.72%)

Piper Sandler analyst…

Piper Sandler analyst Tyler Van Buren raised the firm's price target on Oyster Point Pharma to $60 from $35 and keeps an Overweight rating on the shares. The analyst cites the commentary from the company CEO in Q4 earnings that its ONSET-2 Phase 3 top-line data is expected by the end of Q2 with a planned NDA submission during the second half of 2020. Van Buren adds that he has a "high degree of confidence" in ONSET-2's success based on its magnitude of clinical effect and onset of action that should be " differentiating for a potential label."

ShowHide Related Items >><<
03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Earnings
Oyster Point Pharma reports Q4 ($1.41) vs. ($2.84) last year » 19:18
02/27/20
02/27
19:18
02/27/20
19:18
OYST

Oyster Point Pharma

$34.15 /

-6.37 (-15.72%)

CEO says: "The…

CEO says: "The Oyster Point Pharma team has continued to make excellent progress toward the goal of bringing OC-01 nasal spray to patients with Dry Eye Disease with the MYSTIC study achieving its primary endpoint in Q1 2020 and positive top-line results from the ZEN clinical trial in Q4 2019. I am thankful for all the hard work and dedication of the team and what we have accomplished together in 2019. We expect 2020 to be another transformative year with ONSET-2 Phase 3 top-line data expected by the end of Q2 and a planned NDA submission during the second half of 2020. Other expected key milestones include filing an IND for OC-01 nasal spray in subjects with Neurotrophic Keratitis and continued pipeline development to treat other diseases of the ocular surface."

ShowHide Related Items >><<
03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Hot Stocks
Fly Intel: After Hours Movers » 19:12
02/27/20
02/27
19:12
02/27/20
19:12
SCOR

comScore

$3.00 /

-0.11 (-3.54%)

, FTCH

Farfetch

$9.54 /

-0.33 (-3.35%)

, ZYXI

Zynex

$11.95 /

-0.66 (-5.23%)

, SWN

Southwestern Energy

$1.30 /

-0.11 (-7.83%)

, ICAD

iCAD

$10.86 /

-0.46 (-4.06%)

, NPTN

NeoPhotonics

$6.19 /

-0.125 (-1.98%)

, AMC

AMC Entertainment

$6.08 /

+0.165 (+2.79%)

, TTD

Trade Desk

$250.42 /

-16.58 (-6.21%)

, NKTR

Nektar

$20.59 /

-0.81 (-3.79%)

, FTAI

Fortress Transportation

$18.07 /

-0.8 (-4.24%)

, WDAY

Workday

$171.15 /

-4.19 (-2.39%)

, LYV

Live Nation

$57.73 /

-3.05 (-5.02%)

, OPRX

OptimizeRx

$9.98 /

-1.32 (-11.68%)

, SGMO

Sangamo

$6.67 /

-0.22 (-3.19%)

, FTSV

Forty Seven

$48.78 /

+0.28 (+0.58%)

, BHVN

Biohaven Pharmaceutical

$40.99 /

-3.49 (-7.85%)

, GDI

Gardner Denver

$33.67 /

-2.12 (-5.92%)

, BIG

Big Lots

$22.44 /

-0.36 (-1.58%)

, GPOR

Gulfport Energy

$0.91 /

-0.0949 (-9.44%)

, BYND

Beyond Meat

$106.14 /

-6.31 (-5.61%)

, RUN

Sunrun

$20.32 /

-0.61 (-2.91%)

, CHRS

Coherus Biosciences

$19.18 /

-1.21 (-5.93%)

, GKOS

Glaukos

$61.32 /

-0.03 (-0.05%)

, AAOI

Applied Optoelectronics

$9.56 /

-0.62 (-6.09%)

, VMW

VMware

$135.79 /

-8.51 (-5.90%)

, EB

Eventbrite

$16.98 /

-0.74 (-4.18%)

, AAXN

Axon

$77.16 /

-3.3 (-4.10%)

, MYL

Mylan

$18.62 /

-0.94 (-4.81%)

, IQ

iQIYI

$24.44 /

+0.17 (+0.70%)

, SPPI

Spectrum

$2.41 /

-0.2 (-7.66%)

, DELL

Dell Technologies

$43.63 /

-2.31 (-5.03%)

, CARA

Cara Therapeutics

$15.36 /

-0.55 (-3.46%)

, ADSK

Autodesk

$180.36 /

-10.53 (-5.52%)

, RIGL

Rigel Pharmaceuticals

$2.05 /

-0.13 (-5.96%)

, PSTG

Pure Storage

$15.03 /

-0.835 (-5.26%)

, BBBY

Bed Bath & Beyond

$10.28 /

-0.32 (-3.02%)

UP AFTER EARNINGS:…

UP AFTER EARNINGS: comScore (SCOR) up 20.5%... Farfetch (FTCH) up 15.7%... Zynex (ZYXI) up 11.6%... Southwestern Energy (SWN) up 10.0%... iCAD (ICAD) up 10.0%... NeoPhotonics (NPTN) up 10.0%... AMC Entertainment (AMC) up 8.1%... Trade Desk (TTD) up 6.2%... Nektar Therapeutics (NKTR) up 5.9%...Fortress Transportation (FTAI) up 4.0%... Workday (WDAY) up 2.5%... Live Nation (LYV) up 2.2%... OptimizeRX (OPRX) up 2.1%. ALSO HIGHER: Sangamo (SGMO) up 39.5% after entering gene regulation therapy partnership with Biogen... Forty Seven (FTSV) up 29.1% after Bloomberg speculation about approach from Gilead... Biohaven (BHVN) up 6.0% after getting FDA approval for acute treatment of migraine... Garden Denver (GDI) up 2.1% after entering S&P500 index... DOWN AFTER EARNINGS: Big Lots (BIG) down 28.3%... Gulfport Energy (GPOR) down 11.1%... Beyond Meat (BYND) down 10.0%... Sunrun (RUN) down 10.0%... Coherus BioSciences (CHRS) down 8.8%... Glaukos (GKOS) down 7.5%... Applied Optoelectronics (AAOI) down 6.8%... VMWare (VMW) down 6.0%... Eventbrite (EB) down 5.4%... Axon Enterprise (AAXN) down 4.2%... Mylan (MYL) down 3.6%... iQIYI (IQ) down 3.4%... Spectrum Pharma (SPPI) down 3.3%... Dell Technologies (DELL) down 3.3%... Cara Therapeutics (CARA) down 3.2%... Autodesk (ADSK) down 2.6%... Rigel Pharma (RIGL) down 2.5%... Pure Storage (PSTG) down 2.1%. ALSO LOWER: Bed Bath Beyond (BBBY) down 2.0% after announcing strategic restructuring and job cuts. Movers as of 18:30ET.

ShowHide Related Items >><<
03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Hot Stocks
KKR, IGIS, SK D&D acquire Namsan Square an Seoul » 19:01
02/27/20
02/27
19:01
02/27/20
19:01
KKR

KKR

$28.85 /

-1.35 (-4.47%)

KKR, IGIS Asset…

KKR, IGIS Asset Management, and Korean real estate developer SK D&D announced their acquisition of Namsan Square, an office tower located in the central business district of Seoul, from a real estate investment trust operated by KOREIT, a domestic asset manager in Korea. The consortium plans to enhance the workspace environment by upgrading the building facade, restrooms and the retail arcade without disruption to existing tenants.

ShowHide Related Items >><<
03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Periodicals
Fiat Chrysler to cut about 1,500 jobs in Canada, Bloomberg reports » 18:50
02/27/20
02/27
18:50
02/27/20
18:50
FCAU

Fiat Chrysler

$12.38 /

-0.135 (-1.08%)

Fiat Chrysler is slashing…

Fiat Chrysler is slashing output at its Canadian minivan factory, cutting roughly 1,500 jobs, Bloomberg's Gabrielle Coppola reports. The car maker said it is canceling the third shift at its assembly plant in Windsor, Ontario, staring June 29, adding that it is also phasing out the Dodge Grand Caravan, whose production will cease at the end of May, Coppola says. "This decision comes as the company works to align volumes with demand," Fiat Chrysler spokeswoman Jodi Tinson said in an emailed statement. The company "will make every effort to place indefinitely laid-off hourly employees in open full-time positions as they become available based on seniority." Reference Link

ShowHide Related Items >><<
03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Downgrade
Flir Systems downgraded to Hold from Buy at SunTrust » 18:50
02/27/20
02/27
18:50
02/27/20
18:50
FLIR

Flir Systems

$44.42 /

-9.7 (-17.92%)

SunTrust analyst Michael…

SunTrust analyst Michael Ciarmoli downgraded Flir Systems to Hold from Buy with a price target of $50, down from $61.

ShowHide Related Items >><<
03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Upgrade
Realty Income upgraded to Buy from Hold at Edward Jones » 18:49
02/27/20
02/27
18:49
02/27/20
18:49
O

Realty Income

$72.95 /

-6.81 (-8.54%)

Edward Jones analyst Jim…

Edward Jones analyst Jim Shanahan upgraded Realty Income to Buy from Hold.

ShowHide Related Items >><<
03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27
    Feb
Upgrade
Facebook upgraded to Buy from Hold at Edward Jones » 18:49
02/27/20
02/27
18:49
02/27/20
18:49
FB

Facebook

$189.71 /

-7.38 (-3.74%)

Edward Jones analyst…

Edward Jones analyst David Heger upgraded Facebook to Buy from Hold.

ShowHide Related Items >><<
03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Recommendations
Prescriber enthusiasm for Aimmune's Palforzia robust, says Piper Sandler » 18:36
02/27/20
02/27
18:36
02/27/20
18:36
AIMT

Aimmune

$24.39 /

-2.07 (-7.82%)

Piper Sandler analyst…

Piper Sandler analyst Christopher Raymond keeps his Overweight rating and $60 price target on Aimmune, saying there is no change to his positive view on the company after its Q4 results. With the approval of Parforzia in hand, the analyst anticipates a "meaningful short squeeze" to play out over the next 12 months given that the pre-launch prescriber enthusiasm appears to be both robust and accelerating.

ShowHide Related Items >><<
03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Periodicals
Jury orders J&J pay $9M in talc cancer case, Bloomberg reports » 18:22
02/27/20
02/27
18:22
02/27/20
18:22
JNJ

Johnson & Johnson

$138.96 /

-4.81 (-3.35%)

A Florida jury has…

A Florida jury has ordered Johnson & Johnson to pay $9M to an 82-year-old woman who claimed that asbestos-tainted talc was responsible for her cancer, Bloomberg's Jef Feeley reports. Jurors in Miami determined that asbestos in baby powder used by Blanca Mure-Cabrera throughout her lifetime contributed to the development of her mesothelioma, Feeley notes, citing one of her lawyers. The trial outcome marks the second loss for J&J this year over claims that it was aware some of its talc-based products were laced with asbestos and concealed it from consumers, the author notes. Reference Link

ShowHide Related Items >><<
03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Hot Stocks
SEC fines Wells Fargo $35M over investment recommendation practices » 18:19
02/27/20
02/27
18:19
02/27/20
18:19
WFC

Wells Fargo

$42.45 /

-1.7 (-3.85%)

The Securities and…

The Securities and Exchange Commission announced settled charges against Wells Fargo Clearing Services and Wells Fargo Advisors Financial Network for failing reasonably to supervise investment advisers and registered representatives who recommended single-inverse ETF investments to retail investors, and for lacking adequate compliance policies and procedures with respect to the suitability of those recommendations. The SEC ordered Wells Fargo to pay a $35M penalty, which will be distributed to harmed investors. As noted in the SEC's order and reflected in Wells Fargo's internal guidance, when single-inverse ETFs are held for longer than a day, particularly in volatile markets, investors may experience large and unexpected losses. The SEC's order finds that from April 2012 through September 2019, Wells Fargo's policies and procedures were not reasonably designed to prevent and detect unsuitable recommendations of single-inverse ETFs. Further, Wells Fargo failed adequately to supervise its employees' recommendations regarding single-inverse ETFs, and did not adequately train them concerning those products. The order finds that some Wells Fargo brokers and advisers did not fully understand the risk of losses these complex products posed when held long term. As a result, certain Wells Fargo investment advisers and registered representatives made unsuitable recommendations to certain clients to buy and hold single-inverse ETFs for months or years. According to the order, a number of these clients were senior citizens and retirees who had limited incomes and net worth, and conservative or moderate risk tolerances. Reference Link

ShowHide Related Items >><<
03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Hot Stocks
SPDR Gold Shares holdings fall to 934.23MT from 935.70MT » 18:18
02/27/20
02/27
18:18
02/27/20
18:18
GLD

SPDR Gold Shares

$154.03 /

+0.08 (+0.05%)

This is the 2nd…

This is the 2nd consecutive decline in holdings.

Recommendations
Piper Sandler says Acceleron remains top pick » 18:17
02/27/20
02/27
18:17
02/27/20
18:17
XLRN

Acceleron

$86.34 /

-0.73 (-0.84%)

Piper Sandler analyst…

Piper Sandler analyst Danielle Brill maintained an Overweight rating and $135 price target on Acceleron Pharma, as the reblozyl launch is now underway, and label expansion for MDS is expected by its April 4 PDUFA date. Brill said that while management is reportedly pleased with teh growth they are seeing, they are not anticipating meaningful revenue generation until later this year when MDS starts to ramp. The analyst added that a planned meeting with the FDA to discuss the next steps for development will be a "significant" catalyst, and that Acceleron remains a top pick ahead of sotatercept data at ATS.

ShowHide Related Items >><<
03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Earnings
AG Mortgage reports Q4 EPS 52cc, consensus 44c » 18:15
02/27/20
02/27
18:15
02/27/20
18:15
MITT

AG Mortgage

$15.39 /

-0.73 (-4.53%)

Reports Q4 NII $25.4M vs.…

Reports Q4 NII $25.4M vs. $20.9M last year. "During 2019, MITT completed two capital raises and utilized its ATM program which in total resulted in net proceeds of approximately $177 million," said Chief Executive Officer, David Roberts. "In both cases, we initially deployed the capital into Agency MBS with subsequent rotation into residential and commercial credit investments. We believe these credit investments reflect the benefit MITT offers its shareholders by being part of the broader Angelo Gordon platform. After several challenging quarters for the Agency MBS and rate markets, those headwinds faded and some even turned to tailwinds during the fourth quarter," said Chief Investment Officer, T.J. Durkin. "We were also active in the securitization space. In November, MITT, alongside other Angelo Gordon funds, completed its third rated Non-QM securitization as well as a non-rated securitization of primarily RPLs after exercising call rights. Both securitizations provide MITT with termed-out and materially cheaper cost of funds in comparison to our warehouse lines and previous securitizations."

ShowHide Related Items >><<
Hot Stocks
Gardner Denver to join S&P 500, Cimarex to join S&P MidCap 400 » 18:11
02/27/20
02/27
18:11
02/27/20
18:11
XEC

Cimarex Energy

$30.67 /

-3.21 (-9.47%)

, GDI

Gardner Denver

$33.67 /

-2.12 (-5.92%)

, CHK

Chesapeake

$0.26 /

-0.0488 (-15.80%)

, IR

Ingersoll-Rand

$132.59 /

-6.2 (-4.47%)

, TT

Trane

$0.00 /

+ (+0.00%)

Gardner Denver Holdings…

Gardner Denver Holdings Inc. (GDI) will replace Cimarex Energy Co. (XEC) in the S&P 500, and Cimarex Energy will replace Chesapeake Energy Corp. (CHK) in the S&P MidCap 400 effective prior to the open of trading on Tuesday, March 3. S&P 500 constituent Ingersoll-Rand plc (IR) is spinning off its industrial segment business which will be merged with Gardner Denver Holdings. Post-spin-off, the "old" Ingersoll-Rand will change its name and ticker to Trane Technologies plc (TT), and Trane will remain in the S&P 500 with a Global Industry Classification Standard change to Building Products Sub-Industry classification. Immediately following its merger with the industrial segment business, Gardner Denver will have a name and ticker change to "new" Ingersoll Rand Inc. (IR). Cimarex Energy has a market capitalization more representative of the mid-cap market space. Chesapeake Energy is ranked near the bottom of the S&P MidCap 400 and is no longer representative of the mid-cap market space.

ShowHide Related Items >><<
03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Hot Stocks
LP Building Solutions to sell East River facility and CanExel brand to Maibec » 18:04
02/27/20
02/27
18:04
02/27/20
18:04
LPX

Louisiana-Pacific

$29.12 /

-1.7 (-5.52%)

LP Building Solutions and…

LP Building Solutions and Mailbec announced a joint agreement for Maibec's acquisition of LP's East River facility located in Nova Scotia, Canada as well as the assets and brand rights for CanExel, the fiber-based siding product manufactured there. The closing of this transaction is subject to customary closing conditions and is expected to occur in the second quarter of 2020. "LP's SmartSide strand siding business is one of the fastest-growing siding brands in the U.S.," said Executive Vice President & General Manager of Siding Neil Sherman. "This strategic decision to remove fiber products from our portfolio allows us to mobilize additional resources, increase focus and commitment for our LP SmartSide strand siding technology, and accelerate growth of LP SmartSide ExpertFinish, our new line of prefinished strand-based siding. The future for SmartSide strand is bright, and we expect great things to come."

ShowHide Related Items >><<
03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.